Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) - Mar 7, 2023 - "Actively enrolling patients in TCR-T Library Phase 1/2 trial; expect to report interim data on multiple patients in mid-2023: The Company continues to actively enroll patients in its TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR hotspot mutations across six solid tumor indications....With these enhancements, the Company expects to enroll multiple patients in the months ahead....Expanding application of the hunTR® TCR discovery platform to add additional TCRs to the TCR Library in 2023....Alaunos expects to expand its TCR library to 15 TCRs by the end of 2023."
P1/2 data • Trial status • Biliary Tract Cancer • Cholangiocarcinoma • Colorectal Cancer • Endometrial Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Lung Adenocarcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor
|